Related Experiment Videos
Pretreatment hormone levels in prostatic cancer
R Haapiainen1, S Rannikko, O Alfthan
1Second Department of Surgery, Helsinki University Central Hospital, Finland.
Scandinavian Journal of Urology and Nephrology. Supplementum
|January 1, 1988
Summary
Higher pretreatment estradiol and testosterone levels correlate with improved survival in prostate cancer patients. Prolactin levels did not show a significant association with patient outcomes.
Area of Science:
- Endocrinology
- Oncology
- Urology
Background:
- Hormonal factors play a crucial role in prostate cancer development and progression.
- Understanding the relationship between pretreatment hormone levels and patient outcomes is essential for personalized treatment strategies.
Purpose of the Study:
- To investigate the association between pretreatment plasma concentrations of total testosterone, prolactin, and total estradiol-17 beta (E2) and survival in prostate cancer patients.
- To explore potential differences in hormone levels based on tumor stage.
Main Methods:
- Plasma samples from 123 prostate cancer patients were analyzed for total testosterone, prolactin, and total estradiol-17 beta (E2) before treatment.
- Patients were staged according to the UICC classification.
- Follow-up data was collected over a mean period of 48 months.
Main Results:
- Patients with intracapsular tumors and no metastases exhibited significantly higher pretreatment total estradiol levels compared to those with advanced disease (p < 0.05).
- Elevated pretreatment levels of estradiol and testosterone were associated with improved patient survival.
- Prolactin levels did not appear to be a significant prognostic indicator.
Conclusions:
- Pretreatment estradiol and testosterone levels may serve as potential biomarkers for predicting survival in prostate cancer.
- Estradiol levels might be linked to tumor stage, with lower levels in more advanced disease.
- Prolactin assays are unlikely to be valuable for prognostic assessment in this patient cohort.